Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Healthy Lifestyle Obese Men Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine within the reference range at the time of screening 2. Must have Hispanic Father and Mother from Mexico or Central America 3. Normal weight, active subjects BMI 18.5 9 calculated as weight in Kg/ (height in cm)2 Participates in ≥150 min/week of moderate intensity physical activity as assessed by accelerometer Consume < 30% of calories as fat/day Fasting lipid panel within reference range or not clinically significant above the reference ranges Obese and physically inactive subjects BMI ≥ 30 calculated as weight in Kg/ (height in cm)2 in obese subjects Have risk factors for developing type 2 diabetes (first degree relatives with DM2, BP≥130/80, HDL-cholesterol ≤ 35mg/dL or triglycerides ≥200mg/dL, fasting plasma glucose ≥100mg/dl to 125mg/dL or HgbA1c ≥ 5.7 to 6.4%, abnormal liver transaminases (not more than 3 times upper limit of normal suggestive of hepatic steatosis) Participates in ≤150 min/week of moderate intensity physical activity Consume >30 % fat as calories/day  Men who meet any of the following are NOT eligible for enrollment in the trial: 2. Men participating in another clinical trial within the last 30 days prior to the first screening visit 3. Men not living in the catchment's area of the clinic or within a reasonable distance from the site 4. Clinically significant abnormal findings at screening except for those stated above for the obese, inactive group 5. Abnormal serum chemistry values, according to local laboratory normal values that indicate chronic liver or kidney dysfunction or that may be considered clinically significant (except for obesity related abnormal laboratory tests including blood glucose, Hgb A1c, liver transaminases, lipids for the obese, active group as stated above). Other abnormal lab values may also be exclusionary, at the discretion of the investigator 6. Sperm concentration below 15 million/mL in more than one of three screening samples 7. Diastolic (D) blood pressure (BP) > 30 and Systolic (S) BP > 130 mm Hg for the healthy, non-obese and active group; and diastolic (D) blood pressure (BP) > 150 and Systolic (S) BP > 100 mm Hg for the obese, inactive group on in the opinion of the investigator not suitable for exercise training (BP will be taken 3 times at 5 minute intervals and the mean of all measurements be considered) 8. History of hypertension, including hypertension controlled with treatment in the healthy, active group 9. Known history of reproductive dysfunction including vasectomy or infertility 10. Known history of cardiac, renal, hepatic, cardiac or respiratory disease 11. A serious systemic disease such as diabetes mellitus defined by the American Diabetes Association or morbid obesity (body weight greater than 120% of ideal body weight or BMI limitation as above) 12. Known or suspected alcoholism or drug abuse or chronic infections 13. Serious digestive and/or absorptive problems, including inflammatory bowel disease and 14. Chronic food intolerance or diarrhea that preclude adherence to the study diet. 15. Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. 16. Psychiatric disorders (including eating disorders) or conditions that, in the opinion of the investigator, would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder). 17. History of other malignancies except: adequately treated non-melanoma skin cancer